Third-generation TKI osimertinib can overcome this resistance mechanism, and it has proven to be effective in EGFR-mutated NSCLC irrespective of T790M status, but the clinical benefit would be limited by further emergence of resistance [5,6]. Here, EGFR is linked to non-small cell lung carcinoma.